Screening the Effectiveness of Kabasura Kudineer against COVID 19 and Immune Proteins in Humans: In silico

Background: The advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first century. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has greatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants. However, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and their side effects. Objective: The main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against COVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans. Methods: The molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check the Pharmacokinetics. Results: The results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate. Conclusion: Siddha way of treatment has popped out which has been traditionally used for the treatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven to have antiviral agents and compounds that boost the immune system.